ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, today announced that physicians at all of the 17 “Honor Roll” hospitals and all of the 50 “Best Cardiology and Heart Surgery” hospitals designated by U.S. News and World Report for 2011-2012 have prescribed the ZOLL LifeVest® Wearable Defibrillator for patients.
The LifeVest is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest allows a patient’s physician time to assess their long-term arrhythmic risk and make appropriate plans. The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest does not require bystander intervention and has a 98 percent first treatment shock success rate for resuscitating patients with SCA.
“For the fourth year in a row, physicians at all of the ‘Honor Roll’ and ‘Best Cardiology and Heart Surgery’ hospitals have prescribed the LifeVest to protect their patients from sudden cardiac death,” said Richard A. Packer, Chief Executive Officer of ZOLL. “The fact that physicians at all of these premier institutions prescribe the LifeVest is a testament to the important role this treatment option plays in the standard of care for patients at risk of SCA.”
The LifeVest is used for a wide range of patient conditions, including following a heart attack, before or after bypass surgery or stent placement, as well as cardiomyopathy or congestive heart failure, that place patients at particular risk. To date, the LifeVest has been prescribed to more than 45,000 patients. For more information, go to zoll.com or 1.800.543.3267.
U.S. News and World Report’s “Best Hospitals” is an annual ranking of the country’s elite medical centers that assesses how well a hospital handles complex and demanding situations. From among the 4,825 hospitals considered for the report, only 140 were ranked in one or more of the 16 specialties, and from those, only 17 qualified for the “Honor Roll” designation by earning high scores in at least six specialties. U.S. News and World Report also named the 50 “Best Cardiology and Heart Surgery” hospitals for 2011-2012 based on rankings within the specific category.
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe.
Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, our belief regarding revenues, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on December 17, 2010 and updated in the Company’s Quarterly Reports on Form 10-Q filed subsequently to the Form 10-K. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.
Copyright © 2011 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL is a registered trademark of ZOLL Medical Corporation in the United States and/or other countries. Propaq is a registered trademark of Welch Allyn. All product names are the property of their respective owners.
A. Ernest Whiton, Chief Financial Officer
ZOLL Medical Corporation
P: +1 (978) 421-9655